European investment fund focused in the medical and life science that was seeking to invest in a drug platform opportunity.
Destum Partners leveraged several resources to achieve our clients goals:
• Secondary Market Research: Extensive literature review, public domain analysis and syndicated data review
• Valuation: Market and Transaction Comparables
• Internal Expertise: Several consulting projects completed in CNS and Neuroscience fields that were of relevance our Client
Summary and Results
Destum Partners was engaged to create a due diligence report and asset monetization plan through the completion of a comprehensive analysis designed to increase the probability of a successful exit.
Destum began the DD process by completing a comprehensive review of all available materials related to R&D, pre-clinical & clinical studies, IP, management team, & other critical segments. Through the analysis, Destum was able to isolate areas of potential risk and develop a roadmap to strategically guide R&D and corporate activities (prioritized for potential future capital deployment). Transaction comparable analysis was completed to align the development roadmap with potential timing for securing a strategic partner and full exit. Destum’s analysis weighed the scientific / technical risks of the assets against market forces. We developed an investment strategy that focused allocation of capital towards key activities to advance the assets to key value inflection points.
The final deliverable contained actionable recommendations that our Client used to make a final a go / no-go investment decision.